Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Biotechnology

Healthcare
$3.75 -3.27%

-$0.20 today

Market cap
$226.76M
Beta
0.60
P/E (TTM)
-1.4
EPS (TTM)
-$4.03
52W Low $4.14High $9.94

Volume 0.95M

Average 1.29M

VNDA Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Vanda Pharmaceuticals Inc.NASDAQ: VNDA

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital growth accelerates

Q1 FY2026 change in working capital of $7.89M (cash outflow) rose 312.0% year over year, ahead of the +115.1% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at +11.0% a year.

Context

  • Change in working capital amounted to 3.8% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Change in working capital increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +312.0% holds above the trailing-twelve-month pace of +115.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.89M-360.6% QoQ
Last fiscal yearDec 2025
$8.31M+226.7% YoY
LTMMar 2026
$2.34M+115.1% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+312.0%——
1 year+226.7%——
3-year CAGR+11.0%——
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
8.31M USD
Year-over-year change
+226.7%
4-year CAGR
+32.0%

Change in Working Capital vs competitors

How VNDA compares with its peers on the latest reported figures

  • VNDA's LTM Mar 2026 change in working capital of $2.34M is the 8th largest of the 11 companies compared; the peer median is $1.59M.
  • Its year-over-year change of +115.1% is the 5th highest of 11, against a peer median of -48.4%.
  • Change in working capital amounts to 1.1% of revenue for VNDA, versus a peer median of 159.3%.
VNDA Competitors Peer median
Change in Working Capital for VNDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$26.75M -37.9%—73.3%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$15.79M +1014.2%——
HUMAHumacyte, Inc.LTM Mar 2026$15.14M +208.6%—750.8%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$14.08M +115.1%-24.4%245.3%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$13.89M +159.9%——
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$8.51M -85.7%+46.2%18.8%
SGMTSagimet Biosciences Inc.LTM Mar 2026$3.42M -181.2%——
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$2.34M +115.1%+11.0%1.1%
IMRXImmuneering CorporationLTM Mar 2026$1.66M -293.7%+30.6%—
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$1.52M -58.9%-24.9%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$531K -62.5%——
Peer median (excluding VNDA) $1.59M-48.4%+3.1%159.3%

Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income33.15M6.28M2.51M(18.9M)(220.47M)
Depreciation & Amortization2.84M2.73M3.01M8.13M(950K)
Deferred Income Tax6.75M1.13M(1.29M)(6.48M)81.44M
Stock-Based Compensation15.37M16.28M14.04M12.43M9.47M
Change in Working Capital2.74M6.07M(747K)(6.56M)8.31M
Accounts Receivables(2.47M)(1.09M)(707K)(13.01M)(7.46M)
Inventory(2.23M)(4.48M)(771K)(29K)(3.47M)
Accounts Payables3.04M11.79M(10.98M)1.71M15.82M
Other Working Capital4.4M(151K)11.72M4.78M3.42M
Other Non-Cash Items3.37M(507K)(4.73M)(4.38M)12.76M
Operating Cash Flow64.21M31.98M12.8M(15.76M)(109.44M)
Capital Expenditures(552K)(679K)(383K)(490K)(998K)
Acquisitions (Net)00(100.67M)(4.23M)0
Purchases of Investments(420.46M)(349.26M)(512.61M)(364.77M)(112.38M)
Sales of Investments344.32M399.86M601.6M352.06M208.24M
Other Investing Activities00000
Investing Cash Flow(76.7M)49.93M(12.06M)(17.43M)94.86M
Debt Repayment000(155K)(1.99M)
Common Stock Issued3.55M734K000
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0000(915K)
Financing Cash Flow3.55M734K0(155K)(2.91M)
Effect of Forex Changes(85K)315K47K(163K)126K
Net Change in Cash(9.02M)82.96M792K(33.51M)(17.36M)
Free Cash Flow63.66M31.31M12.42M(16.25M)(110.44M)

Vanda Pharmaceuticals Inc.

NASDAQ:VNDA

Intrinsic Alpha fair value

Locked

Current Price

$3.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.